- Home
- CC
as of 03-13-2026 11:17am EST
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 2.3B | IPO Year: | 2014 |
| Target Price: | $18.44 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | -2.57 | EPS Growth: | -550.88 |
| 52 Week Low/High: | $9.13 - $21.85 | Next Earning Date: | N/A |
| Revenue: | $6,638,000,000 | Revenue Growth: | 7.36% |
| Revenue Growth (this year): | 5.8% | Revenue Growth (next year): | 5.58% |
| P/E Ratio: | -6.89 | Index: | N/A |
| Free Cash Flow: | 51.0M | FCF Growth: | N/A |
AI-Powered CC Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 19, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 19, 2026 · 100% conf.
1D
-5.42%
$19.30
5D
-7.65%
$18.85
20D
-0.33%
$20.34
8-K
0001627223false00016272232026-02-192026-02-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
February 19, 2026 Date of Report (Date of Earliest Event Reported)
The Chemours Company (Exact Name of Registrant as Specified in Its Charter)
Delaware
001-36794
46-4845564
(State or Other Jurisdiction
(Commission
(I.R.S. Employer
Of Incorporation)
File Number)
Identification No.)
1007 Market Street Wilmington, Delaware 19801 (Address of principal executive offices)
Registrant’s telephone number, including area code: (302) 773-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Exchange on Which Registered
Common Stock ($0.01 par value)
CC
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition.
On February 19, 2026, The Chemours Company (the “Company”) issued a press release regarding its fourth quarter and full year 2025 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. The Company will post to its investor relations website, investors.chemours.com, an investor presentation by 8:00 a.m. Eastern Daylight Time on Friday, February 20, 2026, for its conference call scheduled for that time.
The information furnished with this report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it will not be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits 99.1 Press release dated February 19, 2026. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE CHEMOURS COMPANY
By:
/s/ Shane Hostetter
Shane Hostetter
Senior Vice President, Chief Financial Officer
Date:
February 19, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
Q3 2025 Earnings
8-KNov 6, 2025
8-K
false000162722300016272232025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
November 6, 2025 Date of Report (Date of Earliest Event Reported)
The Chemours Company (Exact Name of Registrant as Specified in Its Charter)
Delaware
001-36794
46-4845564
(State or Other Jurisdiction
(Commission
(I.R.S. Employer
Of Incorporation)
File Number)
Identification No.)
1007 Market Street Wilmington, Delaware 19801 (Address of principal executive offices)
Registrant’s telephone number, including area code: (302) 773-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Exchange on Which Registered
Common Stock ($0.01 par value)
CC
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition.
On November 6, 2025, The Chemours Company (the “Company”) issued a press release regarding its third quarter 2025 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. Senior management's prepared remarks are attached as Exhibit 99.2 to this report. The Company will post to its investor relations website, investors.chemours.com, an investor presentation and prepared remarks by 8:00 a.m. Eastern Daylight Time on Friday, November 7, 2025, for its conference call scheduled for that time.
The information furnished with this report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it will not be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits 99.1 Press release dated November 6, 2025. 99.2 The Chemours Company Q3 2025 Financial Results Conference Call Prepared Remarks dated November 6, 2025. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE CHEMOURS COMPANY
By:
/s/ Shane Hostetter
Shane Hostetter
Senior Vice President, Chief Financial Officer
Date:
November 6, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
Q2 2025 Earnings
8-KAug 5, 2025
8-K
false000162722300016272232025-08-052025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
August 5, 2025 Date of Report (Date of Earliest Event Reported)
The Chemours Company (Exact Name of Registrant as Specified in Its Charter)
Delaware
001-36794
46-4845564
(State or Other Jurisdiction
(Commission
(I.R.S. Employer
Of Incorporation)
File Number)
Identification No.)
1007 Market Street Wilmington, Delaware 19801 (Address of principal executive offices)
Registrant’s telephone number, including area code: (302) 773-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Exchange on Which Registered
Common Stock ($0.01 par value)
CC
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2025, The Chemours Company (the “Company”) issued a press release regarding its second quarter 2025 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. Senior management's prepared remarks are attached as Exhibit 99.2 to this report. The Company will post to its investor relations website, investors.chemours.com, an investor presentation and prepared remarks by 8:00 a.m. Eastern Daylight Time on Wednesday, August 6, 2025, for its conference call scheduled for that time.
The information furnished with this report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it will not be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits 99.1 Press release dated August 5, 2025. 99.2 The Chemours Company Q2 2025 Financial Results Conference Call Prepared Remarks dated August 5, 2025. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE CHEMOURS COMPANY
By:
/s/ Shane Hostetter
Shane Hostetter
Senior Vice President, Chief Financial Officer
Date:
August 5, 2025
Compare CC vs Leading Stocks
See how CC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CC Chemours Company (The) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.